Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

About Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC logoHorizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:HZNP
  • CUSIP: 44047T10
  • Web: www.horizonpharma.com
Capitalization:
  • Market Cap: $1.90859 billion
  • Outstanding Shares: 162,709,000
Average Prices:
  • 50 Day Moving Avg: $11.09
  • 200 Day Moving Avg: $14.74
  • 52 Week Range: $9.45 - $23.44
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 9.77
  • P/E Growth: 1.10
Sales & Book Value:
  • Annual Revenue: $997.29 million
  • Price / Sales: 1.96
  • Book Value: $7.41 per share
  • Price / Book: 1.62
Profitability:
  • EBIDTA: $244.98 million
  • Net Margins: -21.26%
  • Return on Equity: 21.51%
  • Return on Assets: 7.29%
Debt:
  • Debt-to-Equity Ratio: 1.56%
  • Current Ratio: 1.67%
  • Quick Ratio: 1.48%
Misc:
  • Average Volume: 4.46 million shs.
  • Beta: 1.86
  • Short Ratio: 2.01
 

Frequently Asked Questions for Horizon Pharma PLC (NASDAQ:HZNP)

What is Horizon Pharma PLC's stock symbol?

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

How will Horizon Pharma PLC's stock buyback program work?

Horizon Pharma PLC announced that its Board of Directors has authorized a stock repurchase plan on Sunday, June 4th 2017, which allows the company to buyback 1,000% of outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

How were Horizon Pharma PLC's earnings last quarter?

Horizon Pharma PLC (NASDAQ:HZNP) announced its quarterly earnings results on Monday, May, 8th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.25 by $0.04. The company had revenue of $220.90 million for the quarter, compared to the consensus estimate of $248.71 million. Horizon Pharma PLC had a negative net margin of 21.26% and a positive return on equity of 21.51%. The company's revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.34 EPS. View Horizon Pharma PLC's Earnings History.

Where is Horizon Pharma PLC's stock going? Where will Horizon Pharma PLC's stock price be in 2017?

12 brokerages have issued twelve-month price targets for Horizon Pharma PLC's shares. Their predictions range from $10.00 to $32.00. On average, they expect Horizon Pharma PLC's stock price to reach $20.42 in the next year. View Analyst Ratings for Horizon Pharma PLC.

What are analysts saying about Horizon Pharma PLC stock?

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

  • 1. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
  • 2. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
  • 3. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)
  • 4. According to Zacks Investment Research, "Horizon’s growth-by-acquisition strategy, through which it actively pursues deals to expand and diversify its portfolio, is encouraging. The Raptor Pharma acquisition to strengthen its rare disease business is impressive. Moreover, the Hyperion and Crealta acquisitions bode well. However, the company’s efforts to expand Actimmune’s label suffered a developmental setback. Actimmune failed in a late-stage Friedreich's ataxia study, which could have given its sales a much-needed boost. Horizon is also involved in patent litigations with quite a few companies. Also, Horizon’s marketed products face intense competition. Pipeline setbacks, competitive pressures, concerns related to the ongoing litigations and focus on drug pricing remain material headwinds. The company has a negative record of earnings surprise in the last four trailing quarters while the estimates are stable ahead of Q4 results." (2/17/2017)
  • 5. Jefferies Group LLC analysts commented, "Q2 results were well ahead of consensus (revs +10%, EPS +11%), driven by stronger revs from primary care products (+$19M vs JEF). This outperformance came despite higher than forecasted expenses (+$7M vs JEF). Mgt also reaffirmed its FY16 guidance – which appears increasingly achievable as improved GtN’s offset softening PCP Rxs." (8/4/2016)

Are investors shorting Horizon Pharma PLC?

Horizon Pharma PLC saw a increase in short interest in June. As of June 15th, there was short interest totalling 14,604,104 shares, an increase of 15.1% from the May 31st total of 12,691,454 shares. Based on an average daily trading volume, of 4,732,157 shares, the days-to-cover ratio is presently 3.1 days. Currently, 9.1% of the company's stock are short sold.

Who are some of Horizon Pharma PLC's key competitors?

Who are Horizon Pharma PLC's key executives?

Horizon Pharma PLC's management team includes the folowing people:

  • Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
  • Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
  • Brian K. Beeler, Executive Vice President, General Counsel
  • David G. Kelly, Executive Vice President, Company Secretary and Managing Director, Ireland
  • John B. Thomas, Executive Vice President, Strategy and Investor Relations
  • Robert F. Carey, Executive Vice President, Chief Business Officer
  • George P. Hampton, Executive Vice President - Orphan and Primary Care Business Units and International Operations
  • Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • Timothy J. Ackerman, Senior Vice President - Commercial Operations
  • Geoffrey M. Curtis, Senior Vice President - Corporate Communications

Who owns Horizon Pharma PLC stock?

Horizon Pharma PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.17%), Vanguard Group Inc. (7.85%), JPMorgan Chase & Co. (3.87%), Janus Capital Management LLC (2.71%), State Street Corp (2.69%) and Alliancebernstein L.P. (2.50%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Who sold Horizon Pharma PLC stock? Who is selling Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, JPMorgan Chase & Co., Kennedy Capital Management Inc., Point72 Asset Management L.P., Stifel Financial Corp, Bank of Montreal Can and Systematic Financial Management LP. Company insiders that have sold Horizon Pharma PLC stock in the last year include Jeffrey W Sherman and Robert Carey. View Insider Buying and Selling for Horizon Pharma PLC.

Who bought Horizon Pharma PLC stock? Who is buying Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Highbridge Capital Management LLC, Janus Capital Management LLC, North Tide Capital LLC, Morgan Stanley, Capital Fund Management S.A., Alliancebernstein L.P. and Vanguard Group Inc.. View Insider Buying and Selling for Horizon Pharma PLC.

How do I buy Horizon Pharma PLC stock?

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Pharma PLC's stock price today?

One share of Horizon Pharma PLC stock can currently be purchased for approximately $12.02.


MarketBeat Community Rating for Horizon Pharma PLC (NASDAQ HZNP)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  443 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  563
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Horizon Pharma PLC (NASDAQ:HZNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $20.42 (69.86% upside)

Analysts' Ratings History for Horizon Pharma PLC (NASDAQ:HZNP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$13.00LowView Rating Details
5/9/2017Citigroup Inc.Lower Price TargetBuy$20.00 -> $13.00MediumView Rating Details
5/9/2017Jefferies Group LLCSet Price TargetBuy$26.00 -> $14.00LowView Rating Details
5/9/2017Stifel NicolausReiterated RatingBuy -> Buy$35.00 -> $20.00HighView Rating Details
5/9/2017Cowen and CompanySet Price TargetOutperform$42.00 -> $20.00MediumView Rating Details
5/9/2017MizuhoDowngradeBuy -> Neutral$22.00 -> $10.00HighView Rating Details
5/9/2017BMO Capital MarketsReiterated RatingBuy$24.00 -> $17.00HighView Rating Details
3/24/2017Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $30.00LowView Rating Details
2/28/2017Morgan StanleyReiterated RatingEqual Weight$20.00N/AView Rating Details
2/27/2017GuggenheimInitiated CoverageBuy$30.00N/AView Rating Details
10/12/2016Goldman Sachs Group, Inc. (The)Set Price TargetBuy$26.00N/AView Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00N/AView Rating Details
11/11/2015WallachBeth CapitalUpgradeBuyN/AView Rating Details
10/22/2015JMP SecuritiesReiterated RatingBuyN/AView Rating Details
7/7/2015Leerink SwannReiterated RatingPositive$37.00N/AView Rating Details
(Data available from 6/27/2015 forward)

Earnings

Earnings History for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Earnings History by Quarter for Horizon Pharma PLC (NASDAQ HZNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017$0.25$0.21$248.71 million$220.90 millionViewListenView Earnings Details
2/27/2017Q416$0.51$0.64$307.93 million$310.30 millionViewListenView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.41$0.59$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.22$0.16$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.19$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.16$0.14$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.10$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Horizon Pharma PLC (NASDAQ:HZNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.10$0.10$0.10
Q3 20171$0.25$0.25$0.25
Q4 20171$0.29$0.29$0.29
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma PLC (NASDAQ:HZNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 83.70%
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Trades by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Michael G GreyDirectorBuy10,000$9.48$94,800.00View SEC Filing  
3/1/2017Robert CareyEVPSell31,808$16.03$509,882.24View SEC Filing  
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Horizon Pharma PLC (NASDAQ:HZNP)
Latest Headlines for Horizon Pharma PLC (NASDAQ:HZNP)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Expect Horizon Pharma PLC (HZNP) to Post $0.12 Earnings Per Share
www.americanbankingnews.com - June 27 at 7:22 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 24 at 6:10 PM
finance.yahoo.com logoHorizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
finance.yahoo.com - June 23 at 6:06 PM
seekingalpha.com logoHorizon Pharma (HZNP) Presents At JMP Securities Life Sciences Conference - Slideshow
seekingalpha.com - June 22 at 11:23 PM
nasdaq.com logoHorizon Pharma plc Partners with Global Genes® to Unite the Rare Disease ...
www.nasdaq.com - June 20 at 6:37 PM
finance.yahoo.com logoHorizon Pharma Gets Health Canada Approval for Procysbi
finance.yahoo.com - June 20 at 6:37 PM
streetinsider.com logoHorizon Pharma (HZNP) Announces Health Canada Approval of PROCYSBI for Treatment of Nephropathic Cystinosis
www.streetinsider.com - June 19 at 4:45 PM
globenewswire.com logoHorizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine ...
globenewswire.com - June 19 at 12:30 PM
finance.yahoo.com logoHorizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis
finance.yahoo.com - June 19 at 12:30 PM
finance.yahoo.com logoValeant: Stop Looking in the Rearview Mirror!
finance.yahoo.com - June 16 at 6:38 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Coverage Initiated by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 16 at 8:48 AM
streetinsider.com logoHorizon Pharma (HZNP) Presents Data Analyses Showing Clinical Benefit of KRYSTEXXA in Patients with Uncontrolled Gout
www.streetinsider.com - June 15 at 12:45 AM
streetinsider.com logoHorizon Pharma (HZNP) Presents Data Analyses Showing Clinical Benefit of KRYSTEXXA in Patients with ... - StreetInsider.com
www.streetinsider.com - June 14 at 11:34 AM
finance.yahoo.com logoEpidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
finance.yahoo.com - June 14 at 11:33 AM
finance.yahoo.com logoHorizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
finance.yahoo.com - June 14 at 11:33 AM
nasdaq.com logoHorizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - June 12 at 6:26 PM
finance.yahoo.com logoHorizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 12 at 6:26 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 6 at 12:52 PM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Lowered to "Hold" at ValuEngine
www.americanbankingnews.com - June 4 at 11:51 AM
americanbankingnews.com logoStock Repurchase Plan Declared by Horizon Pharma PLC (HZNP) Board
www.americanbankingnews.com - June 4 at 11:28 AM
americanbankingnews.com logoZacks: Analysts Expect Horizon Pharma PLC (HZNP) Will Post Quarterly Sales of $235.01 Million
www.americanbankingnews.com - June 3 at 10:30 AM
americanbankingnews.com logo Brokerages Expect Horizon Pharma PLC (HZNP) Will Announce Earnings of $0.12 Per Share
www.americanbankingnews.com - June 1 at 8:32 AM
finance.yahoo.com logoFalling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)
finance.yahoo.com - May 31 at 5:43 PM
nasdaq.com logoHorizon Pharma Enters Oversold Territory (HZNP)
www.nasdaq.com - May 30 at 5:39 PM
bizjournals.com logoTechnical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Neurocrine Biosciences
www.bizjournals.com - May 30 at 10:41 AM
americanbankingnews.com logoShort Interest in Horizon Pharma PLC (HZNP) Drops By 11.2%
www.americanbankingnews.com - May 27 at 7:16 AM
finance.yahoo.com logoETFs with exposure to Horizon Pharma Plc : May 26, 2017
finance.yahoo.com - May 26 at 6:29 PM
feeds.benzinga.com logoHorizon Pharma plc to Participate in Upcoming Conferences
feeds.benzinga.com - May 26 at 8:21 AM
finance.yahoo.com logoHorizon Pharma plc Named One of the Best Workplaces in Chicago by Fortune
finance.yahoo.com - May 25 at 8:57 PM
streetinsider.com logoHorizon Pharma (HZNP) to Sell European Marketing Rights to PROCYSBI and EMEA Rights to QUINSAIR
www.streetinsider.com - May 24 at 10:42 PM
seekingalpha.com logoHorizon Pharma sells certain ex-U.S. rights to Procysbi and Quinsair for $70M - Seeking Alpha
seekingalpha.com - May 24 at 11:40 AM
streetinsider.com logoHorizon Pharma (HZNP) to Sell European Marketing Rights to PROCYSBI and EMEA Rights to QUINSAIR - StreetInsider.com
www.streetinsider.com - May 24 at 11:40 AM
nasdaq.com logoHorizon Pharma plc Announces Agreement to Sell European Marketing Rights to ...
www.nasdaq.com - May 23 at 5:23 PM
finance.yahoo.com logoHorizon Pharma plc Announces Agreement to Sell European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
finance.yahoo.com - May 23 at 5:23 PM
seekingalpha.com logoHorizon Pharma: Primary Care Segment Implodes - Seeking Alpha - Seeking Alpha
seekingalpha.com - May 17 at 10:03 AM
streetinsider.com logoHorizon Pharma (HZNP) Announces District Court Decision to ... - StreetInsider.com
www.streetinsider.com - May 16 at 11:15 AM
streetinsider.com logoHorizon Pharma (HZNP) Announces District Court Decision to Uphold PENNSAID 2% w/w Patent
www.streetinsider.com - May 15 at 5:20 PM
finance.yahoo.com logoHorizon Pharma plc Announces District Court Decision to Uphold PENNSAID® (diclofenac sodium topical solution) 2% w/w Patent
finance.yahoo.com - May 15 at 11:00 AM
americanbankingnews.com logoHorizon Pharma PLC (HZNP) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 12:50 PM
americanbankingnews.com logoJefferies Group Equities Analysts Decrease Earnings Estimates for Horizon Pharma PLC (HZNP)
www.americanbankingnews.com - May 12 at 10:11 AM
finance.yahoo.com logoHorizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare Businesswomen's Association Luminary
finance.yahoo.com - May 11 at 6:24 PM
finance.yahoo.com logoETFs with exposure to Horizon Pharma Plc : May 11, 2017
finance.yahoo.com - May 11 at 6:24 PM
americanbankingnews.com logoMichael G. Grey Buys 10,000 Shares of Horizon Pharma PLC (HZNP) Stock
www.americanbankingnews.com - May 11 at 12:04 AM
finance.yahoo.com logoNuvo Pharmaceuticals™ Announces 2017 First Quarter Results
finance.yahoo.com - May 10 at 6:26 PM
americanbankingnews.com logoZacks: Analysts Anticipate Horizon Pharma PLC (HZNP) Will Announce Quarterly Sales of $308.43 Million
www.americanbankingnews.com - May 10 at 1:04 PM
finance.yahoo.com logoPharma Lobby Ousts 22 Drugmakers Amid U.S. Pricing Debate
finance.yahoo.com - May 9 at 5:36 PM
finance.yahoo.com logoEdited Transcript of HZNP earnings conference call or presentation 8-May-17 11:30am GMT
finance.yahoo.com - May 9 at 12:31 PM
finance.yahoo.com logoHorizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : May 9, 2017
finance.yahoo.com - May 9 at 12:31 PM
finance.yahoo.com logoHorizon Pharma, Inc. -- Moody's affirms Horizon Pharma; revises outlook to negative
finance.yahoo.com - May 9 at 12:31 PM
finance.yahoo.com logoHorizon Pharma Plc :HZNP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 12:31 PM

Social

Chart

Horizon Pharma PLC (HZNP) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by MarketBeat.com Staff